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Recent articles in CMI have described the dis-
semination of metallo-b-lactamase (MBL) genes
conferring resistance to carbapenems [1,2]. Carba-
penem-hydrolysing b-lactamases identified in
Pseudomonas aeruginosa have mostly been of the
IMP and VIM families [3]. Although VIM-1 was
the first determinant described in Europe (in
Italy), VIM-2 determinants have spread world-
wide and have been reported in isolates causing
outbreaks of infection [4]. We wish to report the
first isolation in France of P. aeruginosa isolates
producing the VIM-1 type MBL.
A prospective study was carried out among a
collection of 1400 P. aeruginosa isolates recovered
from 105 French hospitals during 2004–2005.
Twenty-three isolates exhibited resistance to ti-
carcillin, associated with resistance to ceftazidime
or imipenem, but only four were recognised as
MBL producers using Etest strips for MBL detec-
tion (AB Biodisk, Solna, Sweden) [3]. Isolates V4
(Saint Germain-en-Laye) and P0510 (Nantes) were
from urine, whereas V115 (Le Mans) and V1236
(Vannes) were from bronchial aspirates. MICs
were determined by agar dilution and interpreted
as recommended by CLSI guidelines [5], with
P. aeruginosa VR-143 ⁄ 97 (VIM-1-positive) as a
reference strain [6]. All four isolates were resistant
to all available antibiotics, except colimycin,
fosfomycin, amikacin and aztreonam.
PCR with blaVIM- and blaIMP-specific primers,
followed by sequencing, revealed an identical
blaVIM-1 gene in each MBL-positive isolate [7].
PCR mapping [8] and sequencing of the flanking
regions revealed an integron, In70.2, which was
identical to that found in the four P. aeruginosa
isolates described by Lauretti et al. [6]. Conjuga-
tion experiments [7], using the four VIM-1-pro-
ducing isolates as donors, failed to yield
transconjugants. To search for a possible chromo-
somal location of the MBL gene, the I–CeuI
endonuclease technique was used [9]. The
internal blaVIM-1 probe hybridised with a very
large fragment that co-hybridised with the 16S
rRNA probe, indicating a chromosomal location
for the blaVIM-1 gene, as reported previously for
P. aeruginosa VR-143 ⁄ 97 [6].
Pulsed-field gel electrophoresis analysis was
also performed in order to genotype the four
VIM-1-positive isolates [4]. Although V4, V115
and V1236 had been recovered from different
hospitals located at least 200 km from each
other, these isolates were clonally related, while
isolate P0510 belonged to a distinct clone.
Pulsed-field gel electrophoresis analysis also
indicated that those two pulsotypes were differ-
ent from that of the P. aeruginosa VR143 ⁄ 97
strain from Italy [6].
VIM-1 is the second MBL (after VIM-2) that has
been identified as a cause of carbapenem resist-
ance in P. aeruginosa isolates in France. In nearby
European countries (Greece and Italy), VIM-1 is
predominant and has been associated with large
outbreaks of multidrug-resistant P. aeruginosa or
Enterobacteriaceae [3]. In Spain, following the
discovery of VIM-2 in P. aeruginosa, strains of
Escherichia coli and Klebsiella pneumoniae produ-
cing VIM-1 have recently been isolated [3]. Thus,
VIM-1 and VIM-2 may coexist in southern Europe
in P. aeruginosa strains.
Interestingly, the genetic structure surrounding
blaVIM-1 was identical to that reported previously
in Italy [6], which suggests the possibility of a
conserved blaVIM-1 integron structure in non-
clonally related P. aeruginosa isolates, as has also
been suggested recently by Riccio et al. [9].
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Invasive pneumococcal disease in adults in
North-Rhine Westphalia, Germany
10.1111/j.1469-0691.2006.01518.x
The recent paper in CMI by Reinert et al. [1]
presented interesting information on invasive
pneumococcal disease in adults in North-Rhine
Westphalia, Germany, which was collected pro-
spectively. It was reported that blood cultures
were obtained in 464 cases, and that 152 of these
(only 11 grew Streptococcus pneumoniae) were
positive. However, no information was provided
concerning the 141 non-pneumococci isolates.
These data are of extreme importance, as hardly
any data concerning bacteraemic community-
acquired pneumonia are available. It was also
reported that 112 of 464 patients were receiving
antibiotic treatment when the blood cultures were
inoculated. It would be interesting to know how
many of these 112 blood cultures were positive
and which pathogens were cultured.
P. M. Shah
Department of Internal Medicine, J. W. Goethe University,




Our prospective population-based survey [1] of
invasive pneumococcal disease (IPD) among
adults in North-Rhine Westphalia, Germany,
included 202 of the 386 hospitals in the region,
and the 27 microbiological laboratories that sub-
mitted reports of IPD in these hospitals to the
National Reference Centre for Streptococci
(NRCS). In addition, the degree of under-report-
ing in this region was evaluated. All 27 laborat-
ories were asked to provide complete laboratory
records on all cases of IPD, and 16 were able to do
so. Data concerning all IPD isolates sent by each
of these 16 laboratories to the NRCS were linked
to the databases of each laboratory’s information
system. Moreover, in two additional studies, the
frequency of obtaining blood cultures, as well as
the incidence of previous antibiotic therapy, was
analysed in patients with community-acquired
pneumonia (CAP). For the year 2000, the fre-
quency of obtaining blood cultures was deter-
mined for patients admitted to three university
hospitals (Aachen, Du¨sseldorf and Cologne) with
CAP. In addition, in 2001, the frequency of
antibiotic treatment before blood cultures were
obtained from CAP patients was determined by a
detailed analysis of patient histories. As outlined
in our paper in CMI [1], all cases with the
diagnosis of CAP (all diagnostic positions on the
discharge summary) were identified retrospec-
tively on the basis of ICD-10 codes (J13, J15.9,
J18.0, J18.9). Cases were linked with data in the
laboratory information systems of each hospital’s
microbiological laboratory.
Outcome data were obtained for all patients
from the discharge files of the individual hospi-
tals. Therefore, we are not able to provide the
prospective data requested by Professor Shah.
However, we would like to share the retrospec-
tive data for the 152 cases with positive blood
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